MRNA Moderna Inc

Price (delayed)

$163.15

Market cap

$65.51B

P/E Ratio

112.52

Dividend/share

N/A

EPS

$1.45

Enterprise value

$60.3B

Sector: Healthcare
Industry: Biotechnology

Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert ...

Highlights

The company's EPS has surged by 197% YoY and by 174% QoQ
The net income has soared by 180% from the previous quarter
The quick ratio has plunged by 86% YoY and by 5% from the previous quarter
The debt has surged by 58% year-on-year and by 13% since the previous quarter

Key stats

What are the main financial stats of MRNA
Market
Shares outstanding
401.53M
Market cap
$65.51B
Enterprise value
$60.3B
Valuations
Price to earnings (P/E)
112.52
Price to book (P/B)
16.99
Price to sales (P/S)
23.89
EV/EBIT
94.27
EV/EBITDA
81.41
EV/Sales
22.07
Earnings
Revenue
$2.73B
EBIT
$639.65M
EBITDA
$740.74M
Free cash flow
$5.01B
Per share
EPS
$1.45
Free cash flow per share
$12.52
Book value per share
$9.6
Revenue per share
$6.83
TBVPS
$31.74
Balance sheet
Total assets
$12.69B
Total liabilities
$8.86B
Debt
$234M
Equity
$3.84B
Working capital
$3.26B
Liquidity
Debt to equity
0.06
Current ratio
1.39
Quick ratio
1.3
Net debt/EBITDA
-7.03
Margins
EBITDA margin
27.1%
Gross margin
92.6%
Net margin
21.9%
Operating margin
23.2%
Efficiency
Return on assets
8.5%
Return on equity
19.8%
Return on invested capital
80.4%
Return on capital employed
15%
Return on sales
23.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRNA stock price

How has the Moderna stock price performed over time
Intraday
1.65%
1 week
-8.76%
1 month
24.1%
1 year
206.73%
YTD
56.17%
QTD
24.59%

Financial performance

How have Moderna's revenue and profit performed over time
Revenue
$2.73B
Gross profit
$2.53B
Operating income
$633.72M
Net income
$598.17M
Gross margin
92.6%
Net margin
21.9%
The operating income has soared by 183% from the previous quarter
The net income has soared by 180% from the previous quarter
Moderna's operating margin has surged by 124% QoQ and by 102% YoY
The net margin has surged by 124% since the previous quarter and by 102% year-on-year

Growth

What is Moderna's growth rate over time

Valuation

What is Moderna stock price valuation
P/E
112.52
P/B
16.99
P/S
23.89
EV/EBIT
94.27
EV/EBITDA
81.41
EV/Sales
22.07
The company's EPS has surged by 197% YoY and by 174% QoQ
The equity has soared by 134% YoY and by 50% QoQ
MRNA's P/B is 42% above its last 4 quarters average of 12.0
The stock's P/S is 77% below its last 4 quarters average of 103.5

Efficiency

How efficient is Moderna business performance
MRNA's return on equity has surged by 166% since the previous quarter and by 153% year-on-year
Moderna's ROA has soared by 150% from the previous quarter and by 129% YoY
The company's return on sales has surged by 125% QoQ and by 102% YoY

Dividends

What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRNA.

Financial health

How did Moderna financials performed over time
Moderna's total assets is 43% more than its total liabilities
The quick ratio has plunged by 86% YoY and by 5% from the previous quarter
Moderna's total liabilities has surged by 85% QoQ
The debt is 94% smaller than the equity
The equity has soared by 134% YoY and by 50% QoQ
The debt has surged by 58% year-on-year and by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.